USD 11.2
(3.47%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 12.12 Billion USD | 2.37% |
2022 | 11.84 Billion USD | -2.81% |
2021 | 12.18 Billion USD | 8.31% |
2020 | 11.25 Billion USD | 220.35% |
2019 | 3.51 Billion USD | -15.27% |
2018 | 4.14 Billion USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 11.84 Billion USD | -2.35% |
2024 Q3 | 12.25 Million USD | 2.07% |
2024 Q2 | 12.01 Billion USD | 1.41% |
2023 Q1 | 11.5 Billion USD | -2.93% |
2023 FY | 12.12 Billion USD | 2.37% |
2023 Q4 | 12.12 Billion USD | 4.54% |
2023 Q3 | 11.6 Billion USD | 0.58% |
2023 Q2 | 11.53 Billion USD | 0.3% |
2022 Q3 | 11.5 Billion USD | -2.11% |
2022 Q2 | 11.75 Billion USD | -0.81% |
2022 Q1 | 11.84 Billion USD | -2.81% |
2022 FY | 11.84 Billion USD | -2.81% |
2022 Q4 | 11.84 Billion USD | 2.99% |
2021 Q3 | 12.95 Billion USD | 0.86% |
2021 Q2 | 12.84 Billion USD | 161.02% |
2021 FY | 12.18 Billion USD | 8.31% |
2021 Q1 | 4.92 Billion USD | -56.28% |
2021 Q4 | 12.18 Billion USD | -5.9% |
2020 Q4 | 11.25 Billion USD | 0.0% |
2020 FY | 11.25 Billion USD | 220.35% |
2020 Q1 | - USD | 0.0% |
2019 FY | 3.51 Billion USD | -15.27% |
2018 FY | 4.14 Billion USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
AbbVie Inc. | 124.31 Billion USD | 90.244% |
Bristol-Myers Squibb Company | 65.67 Billion USD | 81.533% |
Bristol-Myers Squibb Company Ce | 65.67 Billion USD | 81.533% |
Johnson & Johnson | 98.78 Billion USD | 87.723% |
Eli Lilly and Company | 53.14 Billion USD | 77.178% |
Merck & Co., Inc. | 69.04 Billion USD | 82.433% |
Novartis AG | 53.19 Billion USD | 77.201% |
Pfizer Inc. | 137.21 Billion USD | 91.161% |